ENDPOINTS

Exclusive: Metsera CEO on what it takes to build an obesity biotech in 2025

Metsera, one of the few biotechs to complete an IPO this year, is making its best effort to catch up to the obesity drug giants: Eli Lilly and Novo Nordisk. The startup landed a ...

Mar 27, 2025 - 18:52
 0
Exclusive: Metsera CEO on what it takes to build an obesity biotech in 2025
Metsera, one of the few biotechs to complete an IPO this year, is making its best effort to catch up to the obesity drug giants: Eli Lilly and Novo Nordisk. The startup landed a ...
Read More

Tags:

Previous Article

New York City Indoor Pollution Law Upheld By Federal Court

Next Article

NASA’s Dust Shield Successfully Repels Lunar Regolith on Moon

Related Posts

Stoke CEO Ed Kaye to depart shortly after inking Biogen pact and before its first Phase 3 trial

Stoke CEO Ed Kaye to depart shortly after inking Biogen...

Mar 18, 2025  0

Novartis touts Zolgensma data in older children

Novartis touts Zolgensma data in older children

Mar 19, 2025  0

On the heels of staff cuts, CRISPR Therapeutics COO departs; Changes galore at Bicycle

On the heels of staff cuts, CRISPR Therapeutics COO dep...

Mar 28, 2025  0